Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2015-12-15

AUTHORS

Donald B. Bailey, Elizabeth Berry-Kravis, Anne Wheeler, Melissa Raspa, Florence Merrien, Javier Ricart, Barbara Koumaras, Gerd Rosenkranz, Mark Tomlinson, Florian von Raison, George Apostol

ABSTRACT

BACKGROUND: A phase II randomized, placebo-controlled, double-blind study and subsequent open-label extension study evaluated the efficacy, safety, and tolerability of mavoglurant (AFQ056), a selective metabotropic glutamate receptor subtype-5 antagonist, in treating behavioral symptoms in adolescent patients with fragile X syndrome (FXS). A novel method was applied to analyze changes in symptom domains in patients with FXS using the narratives associated with the clinician-rated Clinical Global Impression-Improvement (CGI-I) scale. METHODS: In the core study, patients were randomized to receive mavoglurant (25, 50, or 100 mg BID) or placebo over 12 weeks. In the extension, patients received 100 mg BID mavoglurant (or the highest tolerated dose) for up to 32 months. Global improvement, as a measure of treatment response, was assessed using the CGI-I scale. Investigators assigning CGI-I scores of 1 (very much improved), 2 (much improved), 6 (much worse), or 7 (very much worse) were provided a standard narrative template to collect further information about the changes observed in patients. Investigator feedback was coded and clustered into categories of improvement or worsening to identify potential areas of improvement with mavoglurant. Treatment effect in each category was characterized using the Cochran-Mantel-Haenszel test. RESULTS: A total of 134 and 103 patients had reached 2 weeks or more of core and extension study treatment, respectively, by the pre-assigned cutoff date for investigator feedback. In the core study, 34 CGI-I scores of 1 or 2 were reported in 28 patients; one patient scored 6. Analysis of the CGI-I narratives did not indicate greater treatment response in patients receiving mavoglurant compared with placebo in any specific improvement domain. There were 54 CGI-I scores of 1 or 2 in 47 patients in the extension study. The most frequently reported categories of improvement were behavior and mood (79.3 and 76.6 % in core and extension studies, respectively), engagement (75.9 and 78.7 %), and communication (69.0 and 61.7 %). CONCLUSIONS: A method was established to capture and categorize FXS symptoms using CGI-I narratives. Although this method did not show benefit of drug over placebo, narratives from investigators were mostly based on parental report and thus do not represent a completely objective alternative assessment. TRIAL REGISTRATION: The studies described are registered at ClinicalTrials.gov with clinical trial identifier numbers NCT01357239 and NCT01433354. More... »

PAGES

1

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s11689-015-9134-5

DOI

http://dx.doi.org/10.1186/s11689-015-9134-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1022422422

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26855682


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "RTI International, Research Triangle Park, Durham, NC USA", 
          "id": "http://www.grid.ac/institutes/grid.62562.35", 
          "name": [
            "RTI International, Research Triangle Park, Durham, NC USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bailey", 
        "givenName": "Donald B.", 
        "id": "sg:person.07477115377.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07477115377.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pediatrics, Neurological Sciences, and Biochemistry, Rush University Medical Centre, Chicago, IL 60612 USA", 
          "id": "http://www.grid.ac/institutes/grid.240684.c", 
          "name": [
            "Department of Pediatrics, Neurological Sciences, and Biochemistry, Rush University Medical Centre, Chicago, IL 60612 USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Berry-Kravis", 
        "givenName": "Elizabeth", 
        "id": "sg:person.01257012130.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01257012130.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "RTI International, Research Triangle Park, Durham, NC USA", 
          "id": "http://www.grid.ac/institutes/grid.62562.35", 
          "name": [
            "RTI International, Research Triangle Park, Durham, NC USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wheeler", 
        "givenName": "Anne", 
        "id": "sg:person.01062777706.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01062777706.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "RTI International, Research Triangle Park, Durham, NC USA", 
          "id": "http://www.grid.ac/institutes/grid.62562.35", 
          "name": [
            "RTI International, Research Triangle Park, Durham, NC USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Raspa", 
        "givenName": "Melissa", 
        "id": "sg:person.0665432052.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665432052.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Neuroscience Development, Novartis Pharma AG, Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Neuroscience Development, Novartis Pharma AG, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Merrien", 
        "givenName": "Florence", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis Pharma, Barcelona, Spain", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Novartis Pharma, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ricart", 
        "givenName": "Javier", 
        "id": "sg:person.01055773603.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01055773603.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Neurodegeneration Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ USA", 
          "id": "http://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Neurodegeneration Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Koumaras", 
        "givenName": "Barbara", 
        "id": "sg:person.01061673153.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01061673153.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Neuroscience Development, Novartis Pharma AG, Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Neuroscience Development, Novartis Pharma AG, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rosenkranz", 
        "givenName": "Gerd", 
        "id": "sg:person.01146717776.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01146717776.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Neuroscience Development, Novartis Pharma AG, Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Neuroscience Development, Novartis Pharma AG, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tomlinson", 
        "givenName": "Mark", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Neuroscience Development, Novartis Pharma AG, Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Neuroscience Development, Novartis Pharma AG, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "von Raison", 
        "givenName": "Florian", 
        "id": "sg:person.01240162273.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240162273.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Neuroscience Development, Novartis Pharma AG, Basel, Switzerland", 
          "id": "http://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Neuroscience Development, Novartis Pharma AG, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Apostol", 
        "givenName": "George", 
        "id": "sg:person.0740345341.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740345341.17"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00213-010-2130-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001304317", 
          "https://doi.org/10.1007/s00213-010-2130-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1744-859x-12-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019279273", 
          "https://doi.org/10.1186/1744-859x-12-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-244x-7-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029566969", 
          "https://doi.org/10.1186/1471-244x-7-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00213-012-2947-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052767455", 
          "https://doi.org/10.1007/s00213-012-2947-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10803-011-1370-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022732103", 
          "https://doi.org/10.1007/s10803-011-1370-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/npp.2011.137", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000014576", 
          "https://doi.org/10.1038/npp.2011.137"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00213-011-2375-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020703347", 
          "https://doi.org/10.1007/s00213-011-2375-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1097/00125817-200105000-00010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017294641", 
          "https://doi.org/10.1097/00125817-200105000-00010"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11689-011-9074-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015670523", 
          "https://doi.org/10.1007/s11689-011-9074-7"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-12-15", 
    "datePublishedReg": "2015-12-15", 
    "description": "BACKGROUND: A phase II randomized, placebo-controlled, double-blind study and subsequent open-label extension study evaluated the efficacy, safety, and tolerability of mavoglurant (AFQ056), a selective metabotropic glutamate receptor subtype-5 antagonist, in treating behavioral symptoms in adolescent patients with fragile X syndrome (FXS). A novel method was applied to analyze changes in symptom domains in patients with FXS using the narratives associated with the clinician-rated Clinical Global Impression-Improvement (CGI-I) scale.\nMETHODS: In the core study, patients were randomized to receive mavoglurant (25, 50, or 100\u00a0mg BID) or placebo over 12\u00a0weeks. In the extension, patients received 100\u00a0mg BID mavoglurant (or the highest tolerated dose) for up to 32\u00a0months. Global improvement, as a measure of treatment response, was assessed using the CGI-I scale. Investigators assigning CGI-I scores of 1 (very much improved), 2 (much improved), 6 (much worse), or 7 (very much worse) were provided a standard narrative template to collect further information about the changes observed in patients. Investigator feedback was coded and clustered into categories of improvement or worsening to identify potential areas of improvement with mavoglurant. Treatment effect in each category was characterized using the Cochran-Mantel-Haenszel test.\nRESULTS: A total of 134 and 103 patients had reached 2\u00a0weeks or more of core and extension study treatment, respectively, by the pre-assigned cutoff date for investigator feedback. In the core study, 34 CGI-I scores of 1 or 2 were reported in 28 patients; one patient scored 6. Analysis of the CGI-I narratives did not indicate greater treatment response in patients receiving mavoglurant compared with placebo in any specific improvement domain. There were 54 CGI-I scores of 1 or 2 in 47 patients in the extension study. The most frequently reported categories of improvement were behavior and mood (79.3 and 76.6\u00a0% in core and extension studies, respectively), engagement (75.9 and 78.7\u00a0%), and communication (69.0 and 61.7\u00a0%).\nCONCLUSIONS: A method was established to capture and categorize FXS symptoms using CGI-I narratives. Although this method did not show benefit of drug over placebo, narratives from investigators were mostly based on parental report and thus do not represent a completely objective alternative assessment.\nTRIAL REGISTRATION: The studies described are registered at ClinicalTrials.gov with clinical trial identifier numbers NCT01357239 and NCT01433354.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s11689-015-9134-5", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1040543", 
        "issn": [
          "1866-1947", 
          "1866-1955"
        ], 
        "name": "Journal of Neurodevelopmental Disorders", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "8"
      }
    ], 
    "keywords": [
      "extension study", 
      "categories of improvement", 
      "treatment response", 
      "selective metabotropic glutamate receptor subtype-5 antagonist", 
      "metabotropic glutamate receptor subtype 5 antagonists", 
      "subsequent open-label extension study", 
      "long-term extension study", 
      "open-label extension study", 
      "Clinical Global Impressions-Improvement scale", 
      "double-blind study", 
      "benefits of drugs", 
      "greater treatment response", 
      "study treatment", 
      "adolescent patients", 
      "therapeutic studies", 
      "patients", 
      "behavioral symptoms", 
      "Haenszel test", 
      "investigator feedback", 
      "global improvement", 
      "Cochran-Mantel", 
      "symptom domains", 
      "parental reports", 
      "CGI", 
      "placebo", 
      "phase II", 
      "treatment effects", 
      "mavoglurant", 
      "cutoff date", 
      "syndrome", 
      "symptoms", 
      "scores", 
      "weeks", 
      "core studies", 
      "tolerability", 
      "investigators", 
      "further information", 
      "study", 
      "antagonist", 
      "months", 
      "response", 
      "drugs", 
      "efficacy", 
      "treatment", 
      "improvement", 
      "total", 
      "adolescents", 
      "mood", 
      "report", 
      "safety", 
      "changes", 
      "categories", 
      "assessment", 
      "potential areas", 
      "FXS", 
      "benefits", 
      "measures", 
      "test", 
      "date", 
      "effect", 
      "analysis", 
      "data", 
      "method", 
      "scale", 
      "area", 
      "feedback", 
      "information", 
      "engagement", 
      "domain", 
      "alternative assessment", 
      "novel method", 
      "communication", 
      "extension", 
      "behavior", 
      "source data", 
      "template", 
      "narratives", 
      "core", 
      "narrative templates", 
      "glutamate receptor subtype-5 antagonist", 
      "receptor subtype-5 antagonist", 
      "subtype-5 antagonist", 
      "clinician-rated Clinical Global Impression-Improvement (CGI-I) scale", 
      "Global Impression-Improvement (CGI-I) scale", 
      "Impression-Improvement (CGI-I) scale", 
      "BID mavoglurant", 
      "standard narrative template", 
      "extension study treatment", 
      "pre-assigned cutoff date", 
      "specific improvement domain", 
      "improvement domain", 
      "FXS symptoms", 
      "objective alternative assessment", 
      "clinical trial identifier numbers NCT01357239", 
      "trial identifier numbers NCT01357239", 
      "identifier numbers NCT01357239", 
      "numbers NCT01357239", 
      "NCT01357239", 
      "NCT01433354", 
      "Clinical Global Impression-Improvement source data", 
      "Global Impression-Improvement source data", 
      "Impression-Improvement source data", 
      "double-blind therapeutic study"
    ], 
    "name": "Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study", 
    "pagination": "1", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1022422422"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s11689-015-9134-5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26855682"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s11689-015-9134-5", 
      "https://app.dimensions.ai/details/publication/pub.1022422422"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:34", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_665.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s11689-015-9134-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s11689-015-9134-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s11689-015-9134-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s11689-015-9134-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s11689-015-9134-5'


 

This table displays all metadata directly associated to this object as RDF triples.

281 TRIPLES      22 PREDICATES      138 URIs      121 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s11689-015-9134-5 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author N9f984c3defa34f9bac7d65048077c5a8
4 schema:citation sg:pub.10.1007/s00213-010-2130-2
5 sg:pub.10.1007/s00213-011-2375-4
6 sg:pub.10.1007/s00213-012-2947-y
7 sg:pub.10.1007/s10803-011-1370-2
8 sg:pub.10.1007/s11689-011-9074-7
9 sg:pub.10.1038/npp.2011.137
10 sg:pub.10.1097/00125817-200105000-00010
11 sg:pub.10.1186/1471-244x-7-7
12 sg:pub.10.1186/1744-859x-12-2
13 schema:datePublished 2015-12-15
14 schema:datePublishedReg 2015-12-15
15 schema:description BACKGROUND: A phase II randomized, placebo-controlled, double-blind study and subsequent open-label extension study evaluated the efficacy, safety, and tolerability of mavoglurant (AFQ056), a selective metabotropic glutamate receptor subtype-5 antagonist, in treating behavioral symptoms in adolescent patients with fragile X syndrome (FXS). A novel method was applied to analyze changes in symptom domains in patients with FXS using the narratives associated with the clinician-rated Clinical Global Impression-Improvement (CGI-I) scale. METHODS: In the core study, patients were randomized to receive mavoglurant (25, 50, or 100 mg BID) or placebo over 12 weeks. In the extension, patients received 100 mg BID mavoglurant (or the highest tolerated dose) for up to 32 months. Global improvement, as a measure of treatment response, was assessed using the CGI-I scale. Investigators assigning CGI-I scores of 1 (very much improved), 2 (much improved), 6 (much worse), or 7 (very much worse) were provided a standard narrative template to collect further information about the changes observed in patients. Investigator feedback was coded and clustered into categories of improvement or worsening to identify potential areas of improvement with mavoglurant. Treatment effect in each category was characterized using the Cochran-Mantel-Haenszel test. RESULTS: A total of 134 and 103 patients had reached 2 weeks or more of core and extension study treatment, respectively, by the pre-assigned cutoff date for investigator feedback. In the core study, 34 CGI-I scores of 1 or 2 were reported in 28 patients; one patient scored 6. Analysis of the CGI-I narratives did not indicate greater treatment response in patients receiving mavoglurant compared with placebo in any specific improvement domain. There were 54 CGI-I scores of 1 or 2 in 47 patients in the extension study. The most frequently reported categories of improvement were behavior and mood (79.3 and 76.6 % in core and extension studies, respectively), engagement (75.9 and 78.7 %), and communication (69.0 and 61.7 %). CONCLUSIONS: A method was established to capture and categorize FXS symptoms using CGI-I narratives. Although this method did not show benefit of drug over placebo, narratives from investigators were mostly based on parental report and thus do not represent a completely objective alternative assessment. TRIAL REGISTRATION: The studies described are registered at ClinicalTrials.gov with clinical trial identifier numbers NCT01357239 and NCT01433354.
16 schema:genre article
17 schema:inLanguage en
18 schema:isAccessibleForFree true
19 schema:isPartOf N5b073e09c69041109dfc74ad397587c4
20 Na758a2a20a8a490c9360e9ee163bdbb2
21 sg:journal.1040543
22 schema:keywords BID mavoglurant
23 CGI
24 Clinical Global Impression-Improvement source data
25 Clinical Global Impressions-Improvement scale
26 Cochran-Mantel
27 FXS
28 FXS symptoms
29 Global Impression-Improvement (CGI-I) scale
30 Global Impression-Improvement source data
31 Haenszel test
32 Impression-Improvement (CGI-I) scale
33 Impression-Improvement source data
34 NCT01357239
35 NCT01433354
36 adolescent patients
37 adolescents
38 alternative assessment
39 analysis
40 antagonist
41 area
42 assessment
43 behavior
44 behavioral symptoms
45 benefits
46 benefits of drugs
47 categories
48 categories of improvement
49 changes
50 clinical trial identifier numbers NCT01357239
51 clinician-rated Clinical Global Impression-Improvement (CGI-I) scale
52 communication
53 core
54 core studies
55 cutoff date
56 data
57 date
58 domain
59 double-blind study
60 double-blind therapeutic study
61 drugs
62 effect
63 efficacy
64 engagement
65 extension
66 extension study
67 extension study treatment
68 feedback
69 further information
70 global improvement
71 glutamate receptor subtype-5 antagonist
72 greater treatment response
73 identifier numbers NCT01357239
74 improvement
75 improvement domain
76 information
77 investigator feedback
78 investigators
79 long-term extension study
80 mavoglurant
81 measures
82 metabotropic glutamate receptor subtype 5 antagonists
83 method
84 months
85 mood
86 narrative templates
87 narratives
88 novel method
89 numbers NCT01357239
90 objective alternative assessment
91 open-label extension study
92 parental reports
93 patients
94 phase II
95 placebo
96 potential areas
97 pre-assigned cutoff date
98 receptor subtype-5 antagonist
99 report
100 response
101 safety
102 scale
103 scores
104 selective metabotropic glutamate receptor subtype-5 antagonist
105 source data
106 specific improvement domain
107 standard narrative template
108 study
109 study treatment
110 subsequent open-label extension study
111 subtype-5 antagonist
112 symptom domains
113 symptoms
114 syndrome
115 template
116 test
117 therapeutic studies
118 tolerability
119 total
120 treatment
121 treatment effects
122 treatment response
123 trial identifier numbers NCT01357239
124 weeks
125 schema:name Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study
126 schema:pagination 1
127 schema:productId N0743ed10d51544c3956740301c99995b
128 N2a56d7fc7340465cb4cd4d9eacdcdd64
129 Nb91af19d7ed748a69ec9fcc21ea45fab
130 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022422422
131 https://doi.org/10.1186/s11689-015-9134-5
132 schema:sdDatePublished 2021-12-01T19:34
133 schema:sdLicense https://scigraph.springernature.com/explorer/license/
134 schema:sdPublisher N6ccc3440d7be4a299182d74d97666ee7
135 schema:url https://doi.org/10.1186/s11689-015-9134-5
136 sgo:license sg:explorer/license/
137 sgo:sdDataset articles
138 rdf:type schema:ScholarlyArticle
139 N0131a3bf31034cb38cf55e5654996c08 rdf:first N8725efc445534adbbd9627b76b25a01e
140 rdf:rest N7bbdaf452be944ed969d34c937449eb3
141 N02768969814c400eb3a650728a29db2f schema:affiliation grid-institutes:grid.419481.1
142 schema:familyName Tomlinson
143 schema:givenName Mark
144 rdf:type schema:Person
145 N0743ed10d51544c3956740301c99995b schema:name dimensions_id
146 schema:value pub.1022422422
147 rdf:type schema:PropertyValue
148 N0c70bb9874744efc94239bc87a2b9cd9 rdf:first sg:person.01062777706.40
149 rdf:rest Neb4aaa51fe774bdfbfb88b49497041e8
150 N24d741d525874911a9819d19b5a39998 rdf:first sg:person.01257012130.41
151 rdf:rest N0c70bb9874744efc94239bc87a2b9cd9
152 N29c6da4fb88d4a8a9722c8b5595e593b rdf:first sg:person.0740345341.17
153 rdf:rest rdf:nil
154 N2a56d7fc7340465cb4cd4d9eacdcdd64 schema:name pubmed_id
155 schema:value 26855682
156 rdf:type schema:PropertyValue
157 N5b073e09c69041109dfc74ad397587c4 schema:volumeNumber 8
158 rdf:type schema:PublicationVolume
159 N6ccc3440d7be4a299182d74d97666ee7 schema:name Springer Nature - SN SciGraph project
160 rdf:type schema:Organization
161 N7bbdaf452be944ed969d34c937449eb3 rdf:first sg:person.01055773603.79
162 rdf:rest Nc6dee1bd4b34472eae8d44cf70a99259
163 N7e897bf0cf2846749e28ff4ef19682d0 rdf:first N02768969814c400eb3a650728a29db2f
164 rdf:rest N8f5e61778fe4401389b757b5dc79108e
165 N830cdff35a4d4e12bc60077b4f7e276f rdf:first sg:person.01146717776.25
166 rdf:rest N7e897bf0cf2846749e28ff4ef19682d0
167 N8725efc445534adbbd9627b76b25a01e schema:affiliation grid-institutes:grid.419481.1
168 schema:familyName Merrien
169 schema:givenName Florence
170 rdf:type schema:Person
171 N8f5e61778fe4401389b757b5dc79108e rdf:first sg:person.01240162273.44
172 rdf:rest N29c6da4fb88d4a8a9722c8b5595e593b
173 N9f984c3defa34f9bac7d65048077c5a8 rdf:first sg:person.07477115377.43
174 rdf:rest N24d741d525874911a9819d19b5a39998
175 Na758a2a20a8a490c9360e9ee163bdbb2 schema:issueNumber 1
176 rdf:type schema:PublicationIssue
177 Nb91af19d7ed748a69ec9fcc21ea45fab schema:name doi
178 schema:value 10.1186/s11689-015-9134-5
179 rdf:type schema:PropertyValue
180 Nc6dee1bd4b34472eae8d44cf70a99259 rdf:first sg:person.01061673153.64
181 rdf:rest N830cdff35a4d4e12bc60077b4f7e276f
182 Neb4aaa51fe774bdfbfb88b49497041e8 rdf:first sg:person.0665432052.49
183 rdf:rest N0131a3bf31034cb38cf55e5654996c08
184 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
185 schema:name Medical and Health Sciences
186 rdf:type schema:DefinedTerm
187 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
188 schema:name Clinical Sciences
189 rdf:type schema:DefinedTerm
190 sg:journal.1040543 schema:issn 1866-1947
191 1866-1955
192 schema:name Journal of Neurodevelopmental Disorders
193 schema:publisher Springer Nature
194 rdf:type schema:Periodical
195 sg:person.01055773603.79 schema:affiliation grid-institutes:None
196 schema:familyName Ricart
197 schema:givenName Javier
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01055773603.79
199 rdf:type schema:Person
200 sg:person.01061673153.64 schema:affiliation grid-institutes:grid.418424.f
201 schema:familyName Koumaras
202 schema:givenName Barbara
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01061673153.64
204 rdf:type schema:Person
205 sg:person.01062777706.40 schema:affiliation grid-institutes:grid.62562.35
206 schema:familyName Wheeler
207 schema:givenName Anne
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01062777706.40
209 rdf:type schema:Person
210 sg:person.01146717776.25 schema:affiliation grid-institutes:grid.419481.1
211 schema:familyName Rosenkranz
212 schema:givenName Gerd
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01146717776.25
214 rdf:type schema:Person
215 sg:person.01240162273.44 schema:affiliation grid-institutes:grid.419481.1
216 schema:familyName von Raison
217 schema:givenName Florian
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240162273.44
219 rdf:type schema:Person
220 sg:person.01257012130.41 schema:affiliation grid-institutes:grid.240684.c
221 schema:familyName Berry-Kravis
222 schema:givenName Elizabeth
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01257012130.41
224 rdf:type schema:Person
225 sg:person.0665432052.49 schema:affiliation grid-institutes:grid.62562.35
226 schema:familyName Raspa
227 schema:givenName Melissa
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0665432052.49
229 rdf:type schema:Person
230 sg:person.0740345341.17 schema:affiliation grid-institutes:grid.419481.1
231 schema:familyName Apostol
232 schema:givenName George
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740345341.17
234 rdf:type schema:Person
235 sg:person.07477115377.43 schema:affiliation grid-institutes:grid.62562.35
236 schema:familyName Bailey
237 schema:givenName Donald B.
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07477115377.43
239 rdf:type schema:Person
240 sg:pub.10.1007/s00213-010-2130-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001304317
241 https://doi.org/10.1007/s00213-010-2130-2
242 rdf:type schema:CreativeWork
243 sg:pub.10.1007/s00213-011-2375-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020703347
244 https://doi.org/10.1007/s00213-011-2375-4
245 rdf:type schema:CreativeWork
246 sg:pub.10.1007/s00213-012-2947-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1052767455
247 https://doi.org/10.1007/s00213-012-2947-y
248 rdf:type schema:CreativeWork
249 sg:pub.10.1007/s10803-011-1370-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022732103
250 https://doi.org/10.1007/s10803-011-1370-2
251 rdf:type schema:CreativeWork
252 sg:pub.10.1007/s11689-011-9074-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015670523
253 https://doi.org/10.1007/s11689-011-9074-7
254 rdf:type schema:CreativeWork
255 sg:pub.10.1038/npp.2011.137 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000014576
256 https://doi.org/10.1038/npp.2011.137
257 rdf:type schema:CreativeWork
258 sg:pub.10.1097/00125817-200105000-00010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017294641
259 https://doi.org/10.1097/00125817-200105000-00010
260 rdf:type schema:CreativeWork
261 sg:pub.10.1186/1471-244x-7-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029566969
262 https://doi.org/10.1186/1471-244x-7-7
263 rdf:type schema:CreativeWork
264 sg:pub.10.1186/1744-859x-12-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019279273
265 https://doi.org/10.1186/1744-859x-12-2
266 rdf:type schema:CreativeWork
267 grid-institutes:None schema:alternateName Novartis Pharma, Barcelona, Spain
268 schema:name Novartis Pharma, Barcelona, Spain
269 rdf:type schema:Organization
270 grid-institutes:grid.240684.c schema:alternateName Department of Pediatrics, Neurological Sciences, and Biochemistry, Rush University Medical Centre, Chicago, IL 60612 USA
271 schema:name Department of Pediatrics, Neurological Sciences, and Biochemistry, Rush University Medical Centre, Chicago, IL 60612 USA
272 rdf:type schema:Organization
273 grid-institutes:grid.418424.f schema:alternateName Neurodegeneration Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ USA
274 schema:name Neurodegeneration Global Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ USA
275 rdf:type schema:Organization
276 grid-institutes:grid.419481.1 schema:alternateName Neuroscience Development, Novartis Pharma AG, Basel, Switzerland
277 schema:name Neuroscience Development, Novartis Pharma AG, Basel, Switzerland
278 rdf:type schema:Organization
279 grid-institutes:grid.62562.35 schema:alternateName RTI International, Research Triangle Park, Durham, NC USA
280 schema:name RTI International, Research Triangle Park, Durham, NC USA
281 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...